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The migration, proliferation and organization of cells in
tissues are controlled by several forms of intercellular commu-
nication. One form of control involves a network of diffusible
polypeptide growth factors that activate membrane receptors
and transduce proliferative signals. One of these growth fac-
tors, platelet-derived growth factor (PDGF), has provided a
framework for understanding the cellular and molecular events
that underlie the biological effects of a number of growth
factors. PDGF is a family of several closely related 30 kDa
dimers consisting of two disulfide-bonded polypeptide chains,
designated A and B [reviewed in 1]. All three isoforms of PDGF
(AA-, AB- and BB) are biologically active. Two distinct PDGF
receptors have been identified: one that binds either to the A- or
the B-chain (the ct subunit) and one that binds only the B-chain
(the p subunit) [reviewed in 2]. The capacity of cells to respond
to PDGF depends upon the presence of a particular dimeric
form of PDGF as well as expression of appropriate receptors.
PDGF is both mitogenic and chemotactic for cells such as
fibroblasts, smooth muscle cells and glial cells [reviewed in 3].
Because of these properties, PDGF has been implicated in
stimulating the proliferation and cell movement of cells in
normal developmental and reparative responses (for example,
wound healing), as well as in pathologic processes, such as
atherosclerosis and neoplasia. However, there is little compel-
ling evidence that PDGF actually plays a critical role in any of
these processes in vivo. To fully evaluate the possible functions
of PDGF, a detailed description of ligand production, as well as
PDGF receptor expression, is required in each of these settings.
Surprisingly, such documentation is only preliminary. Standard
approaches to localize PDGF expression in vivo have employed
either immunohistochemistry or in situ hybridization. How-
ever, these methods have several potential disadvantages: first,
PDGF is a secreted protein, which implies that cytoplasmic
levels of the protein in intact animals may be low; second,
isoform-specific antibodies which cross species are not readily
available; and third, transcript levels of PDGF B-chain may be
low in vivo because the mRNA has a short half-life. To
circumvent these potential problems, a different approach was
taken.
A transgenic model to study PDGF expression in vivo
A transgenic model was generated to monitor PDGF gene
expression in vivo in which a standard marker gene bacterial
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chioramphenicol-acetyltransferase (CAT) was placed under the
transcriptional control of the human PDGF promoter. This
approach, which has been used by other investigators inter-
ested in the regulation of tissue-specific gene expression [re-
viewed in 4], has multiple advantages: first, by placing this
fusion gene in the germ line of a mouse, a direct measure of the
transcriptional activity of the endogenous PDGF B-chain pro-
moter in vivo can be obtained by measuring CAT activity in
organ extracts; second, CAT is not secreted and should accu-
mulate when the transgene is activated; third, there is no
endogenous CAT activity in the mouse; and finally, CAT assays
on organ extracts are simple to perform and quite sensitive.
However, it is important to note that other structural elements
in the PDGF-B chain gene, not present in the transgene, may
regulate expression of the gene in specific situations. For
example, the B-chain gene may contain cryptic promoter se-
quences or it could contain regulatory elements outside the
existing 5' flanking sequences which could effect the pattern or
extent of expression of the B-chain gene in some tissues.
To obtain the human PDGF-B chain promoter, a recombinant
human genomic library was screened with a partial endothelial
eDNA clone [5]. The 5' end of the phage clone (lambda SIS-A)
[6] was subcloned and designated pSIS-l (Fig. 1). The transgene
was assembled by taking the promoter and adjacent 5' flanking
region (—1366 to + 100 bp) of the human PDGF B-chain from
p515-i and inserting it upstream of the CAT gene, as described
in detail elsewhere [7]. The general architecture of the trans-
gene is illustrated in Figure 2. Transgenic mice were generated
using standard techniques as described elsewhere [8]. Mice
harboring the transgene were determined by Southern blot
analysis of DNA obtained from the tail tissue. Several founder
mice were obtained which contained the transgene. Approxi-
mate copy number was determined by dot blot analysis (Fig. 3)
and ranged from several to several thousand copies. Subse-
quent breeding of the founder animals established three lines,
designated B5, B19 and D29. These lines were chosen because
they carried low, intermediate, and high copy numbers of the
construct. In each of these lines, the integration sites were
unique and the transgene was oriented in a head-to-tail fashion
(data not shown). Pedigrees of these lines showed a pattern of
inheritance consistent with a single autosomal locus.
CAT expression in the transgenic model
Analysis of CAT activity in extracts from a variety of
different organs revealed that CAT activity was highest in the
brain and spinal cord (Fig. 4). Lower levels of activity could be
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Fig. 1. Structure of the human PDGF-B
4 chain gene. Each B-chain exon is numberedJ and the coding regions of each exon are
shaded. Selected restriction sites on both the
genomic phage clone and a plasmid subclone
containing the promoter are indicated.
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Fig. 2. Schematic diagram of the PDGF promoter-CAT lransgene. D21
seen in the heart, eye and aorta. Within the brain, a high level
of transgene expression was found in the cortex, cerebellum,
brain stem, and olfactory bulb [7].
The expression of the hybrid gene was further localized using
an immunohistochemical analysis and an antibody reacting with
CAT. Intracellular staining was observed in a variety of neu-
ronal cell bodies with occasional extension into axons [7].
Positive staining was seen in many neurons of the hippocampal
formation including both dentate gyrus neurons and pyramidal
cells as well as in cortical neurons and scattered neurons of
deep grey structures. In the cerebellum, reactivity was seen in
Purkinje cells, neurons of the deep nuclei and, to a much lower
extent, in granule cells. In the spinal cord, diffuse staining was
seen in the grey matter but not in the white matter. Sections of
dorsal root ganglia showed positive staining of the large sensory
neurons. Glial cells, white matter, ependymal cells and vascular
endothelial cells were negative for immunochemically-detect-
able transgene expression.
Expression of authentic PDGF in the brain of adult mice
The pattern of marker gene expression from the PDGF-
promoter-CAT fusion gene in the transgenic mouse was re-
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Fig. 3. PDGF B-chain promoter-CAT fusion gene copy number in
transgenic mice. The number of fusion genes in each line of founder
transgenic mice is illustrated using the dot blot assay.
markably similar to the pattern of localization of the authentic
PDGF B-chain in monkey brain observed by immunocytochem-
ical analysis using a monoclonal antibody against the B-chain of
PDGF [7]. Immunohistochemical staining of authentic PDGF
B-chain protein was also observed in neurons in the cerebral
cortex, hypothalamus, spinal cord and brain stem nuclei.
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Fig. 4. Expression of CAT activity in the transgenic animals. CAT
assays of organ extracts in an adult mouse, F3 generation. Samples (25jzg of protein) from the homogenates of the indicated organs were
assayed for CAT activity as described elsewhere [7]. Abbreviations are:
C +-positive control, using 0.1 U of a purified CAT enzyme preparation;
C-no extract; Br-brain; H-heart; L-lung; St-stomach; Li-liver; Sp-
spleen; Pa-pancreas; Ki-kidney; M-muscle; Sk-skin; LN-lymph node;
SC-spinal cord; E-eye; To-Tongue, ES-esophagus, D-duodenum, Co-
colon, Ad-adrenal, Ao-aorta; Bi-blood; SV-seminal vesicle; Te-testis.
To confirm that the pattern of transgene expression in the
mice reflects transcription of the endogenous PDGF genes, the
presence of the mRNAs for the A- and B-chains of PDGF, as
well as the /3-type PDGF receptor, was confirmed using the
polymerase chain reaction (PCR). Total RNA isolated from
various regions of the mouse brain was transcribed by reverse
transcriptase and the cDNA was amplified using a "nested" set
of primers by PCR (Fig. 5). The PCR primers were chosen so
that the corresponding mouse and human sequences were
identical. Using these primers, amplification of unprocessed
RNA or genomic DNA would generate significantly longer
fragments. The PCR products from mouse brain were identical
in size to the products amplified from cells known to express the
PDGF genes (Fig. 5). Additionally, cloning and subsequent
DNA sequence analysis of the PCR products confirmed their
Fig. 5. Detection of PDGF A- and B-chains, and PDGF [3-type recep-
tor in different regions of the mouse brain by PCR. Total RNA was
extracted from different regions of the brain and spinal cord using
standard procedures. The nested PCR was performed as described
elsewhere 19]. The PDGF A chain primer used for cDNA synthesis was
CTTCGGACACAGTTTTTCACGGAGGAGAAC, and for the first round
of PCR-GTGGCCAAAGTGGAGTATGTCAGGAAGAAG; nested set of
primers: GAAAGAGGTCCAGGTGAGGTTAGAGG and CACCATA-
CATAGTATGTFCAGGAATG. The primer used for PDGF B-chain
cDNA synthesis was CCGTCCGAATCAGGCATCGAGACAGACGG,
and for first round of PCR ATCGCCGAGTGCAAGACGCGCACA-
GAGGT; nested set of primers: AGGGTCTCCTTCAGGGCCGCCT-
TGTCATG and GTGGAGGTGCAGCGCTGCTCCGGCTGCTG. The
primer used for cDNA synthesis of the PDGF /3-receptor was: AAC-
TCCTCATCTACCTGCTGGTACTTC, and for the first round of PCR-
TGACTGGGGAGAGTGACGGTGGCTACATGG. The nested set of
primers was: TACGTGCCCATGTTGGACATGAAAGGAGAC and
AGCCTCTCCAGGAGCAGCACCAGCTGG. The predicted sizes of
the amplification products are 344 bp for the PDGF B-chain, 174 bp for
the short form and 243 bp for the long isoform of the A-chain of PDGF,
and 629 bp for the PDGF /3-receptor. Abbreviations: reagent control-
amplification reactions containing no template cDNA; HUVEC-human
umbilical vein endothelial cell RNA; HUSMC-human uterine smooth
muscle cell RNA; markers-X174 DNA digested with HaeIII.
identity with the corresponding endogenous murine genes (data
not shown). All regions of the mouse brain expressed tran-
scripts for the B-chain of PDGF as well as the PDGF /3-type
receptor, consistent with the Northern blot findings and the
immunostaining results [7]. The PCR primers for the A-chain of
PDGF were chosen to correspond to exons 5 and 7 in both the
mouse and human A-chain genes [9—Il]. The presence of two
amplified bands (Fig. 5, arrowheads) confirms the alternative
usage of exon 6 of the A-chain gene in the mouse, as in other
'V
C+C—BrH L St Li SpPaRKLKM
ft. B
o 0 to o a oc.tao 0
C+C—BrH L St Li SpPaAdRKLKM
C
,?. ?ø""S 0 10000 Os
Fries and Collins: PDGF expression in a transgenic model 587
species [11—13]. Both the short and long forms of A-chain RNAs
were seen in all parts of the brain.
Several points can be made about these findings: first, these
studies reveal a novel feature of the PDGF-B chain promoter
and 5' flanking sequences, namely, that this region of the PDGF
B-chain gene contains an element(s) capable of efficiently
directing gene expression in neurons. Second, they demon-
strate that the pattern of expression of the transgene in the brain
is similar to the pattern of expression of the authentic PDGF
B-chain gene. Third, CAT activity in the transgenic animals
correlated with PDGF B-chain transcript levels. Finally,
expression of PDGF-B chain by neurons may have several
functions: it could be neurotrophic or chemotactic for develop-
ing neurons, since some neurons express PDGF-/3 receptors, or
it could modulate interactions with glial cells.
Using this fusion gene transgenic model, it has been possible
to monitor the transcriptional activity of the endogenous murine
PDGF B-chain promoter during a variety of pathophysiologic
responses (Fries and Collins, unpublished data). In subsequent
paragraphs, results of preliminary studies will be discussed
exploring the role of the B-chain of PDGF in the renal hyper-
trophy that occurs as a response to functional nephron loss, as
well as in a model of acute ureteral obstruction.
PDGF B-chain expression following unilateral nephrectomy
The phenomenon of renal enlargement following unilateral
nephrectomy has been studied in an effort to identify the
mechanism(s) by which renal cells are induced to increase in
size and number. Thus far, hemodynamic factors leading to an
increased single nephron glomerular filtration rate, as well as
strain and possible sex differences in the ability of the kidney to
react to the loss of functioning nephrons, have been interpreted
as mediators leading to compensatory renal hypertrophy [14].
Conditions such as sustained feeding of protein-rich diets,
diabetes mellitus and pregnancy seem to further promote hy-
pertrophy by enhancing the hemodynamic factors [15]. How-
ever, these hemodynamic factors do not fully explain the
localized compensatory growth in the kidney following reduc-
tion in renal mass. Local production of growth factors within
the kidney could potentially mediate this compensatory growth.
While the search for a specific "renotrophic" factor has not yet
been successful, several factors have been reported whose
strong mitogenic potential for various renal cell lines makes
them possible candidates as direct mediators of renal hypertro-
phy. Since PDGF can function as a mitogen for cells cultured
from the glomerulus [16], we utilized the transgenic model to
investigate whether the PDGF B-chain gene was activated
during the renal hypertrophy following unilateral nephrectomy.
Several different time points were chosen post-nephrectomy; an
early one (3 days), as well as later ones (4 weeks and 4 months)
which corresponded to the period in which a continuous in-
crease in renal mass was occurring. Following nephrectomy a
slow accumulation of a small amount of the transgene product
was seen (Fig. 6). Immunohistochemical analysis will be nec-
essary to elucidate which cell type(s) may be participating in
this process. These findings may indicate a role for PDGF
B-chain transcription during renal cell hypertrophy, however,
the extent of transgene activation was not striking and was not
consistent with the kinetics or the amount of compensatory
growth occurring in the kidney following nephrectomy.
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Fig. 6. Activation of trans gene expression following unilateral ne-
phrectomy. The left kidney was removed and animals were kept for 3
days (A), 4 weeks (B), or 4 months (C), at which point CAT assays were
performed. Abbreviations are defined in Figure 4.
PDGF B-chain expression in acute unilateral ureteral
obstruction
Acute unilateral ureteral obstruction is associated with a
series of renal alterations which include a decline in renal
function, extratubular protein deposits, focal inflammatory cell
infiltration and progressive scarring in the ipsilateral kidney,
and hypertrophy as well as increased function in the contralat-
eral kidney [17]. The mechanisms underlying these changes are
not well understood. The possibility that acute unilateral ure-
teral obstruction activated PDGF B-chain expression was ex-
plored using the transgenic mice. Twenty-four hours after
ligation of the left ureter, CAT activity was measured in both
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Fig. 7. Activation of transgene expression
following acute ureteral obstruction. In the
experimental animals the distal left ureter was
ligated for 24 hours, while the normal controls
were sham operated. CAT assays were
C+ C— Br RK LK RU LU BI Br RK LK RU LU BI performed on selected organs. Abbreviations
used in addition to those in Figure 5 include:
RK-right kidney; LK-left kidney; RU-rightUreter ligation ureter; LU-left ureter.
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the ipsilateral and contralateral ureters and kidneys. In compar-
ison to the normal ureter, CAT activity was induced in the
contralateral ureter, as well as in the obstructed ureter (Fig. 7).
Neither the obstructed kidney or the contralateral kidney
showed a significant transgene activation, relative to a normal
control. Activation of the B-chain of PDGF may be important in
modulating early inflammatory cell infiltration into the ipsilat-
eral ureter, as well as the process of compensatory hypertrophy
in the contralateral ureter.
Transgenic animal models of renal disease
The role of growth factors in normal kidney development, as
well as in pathophysiologic settings, can be examined using
transgenic animals. Thus far, analysis of transgenic mouse
models over expressing growth hormone and growth hormone
releasing factor [reviewed in 181 has suggested a role for these
factors in the development of glomerular hypertrophy and
subsequent sclerosis. In our transgenic model, studying PDGF
B-chain expression in the kidney after unilateral nephrectomy,
the B-chain product may be involved in the later phases of
adaptation to nephron loss following changes in intraglomerular
hemodynamics. Our data indicating that unilateral ureteral
obstruction leads to an increase in PDGF B-chain in the dilated
ureters, and not in the kidney, supports the hypothesis that
increased B-chain expression is not an immediate event follow-
ing the hemodynamic changes in the kidney. However, in
chronic animal models, such as in mesangial proliferative
glomerulonephritis, our transgenic mouse model may be useful
to investigate the mechanisms of increased PDGF B-chain gene
expression.
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